We observed a significant increase in plasma HE4 expression of BC patients in the early stages (stages I and II) compared with healthy individuals; thus, measuring plasma HE4 levels prior to the surgery can potentially discriminate patients and also serve as a serological marker for early detection of primary and/or recurrent BC. The gene discussed is WFDC2; the disease is breast cancer.